scispace - formally typeset
Y

Yu Yamaguchi

Researcher at Nagasaki University

Publications -  12
Citations -  212

Yu Yamaguchi is an academic researcher from Nagasaki University. The author has contributed to research in topics: Osteoclast & RANKL. The author has an hindex of 6, co-authored 12 publications receiving 152 citations.

Papers
More filters
Journal ArticleDOI

Fisetin inhibits osteoclastogenesis through prevention of RANKL-induced ROS production by Nrf2-mediated up-regulation of phase II antioxidant enzymes.

TL;DR: Effects of fisetin, a natural bioactive flavonoid that has been reported to induce HO-1 expression, on the differentiation of macrophages into OCLs are investigated and it is demonstrated that regulation of heme-oxygenase 1 (HO-1) also functions in OCL differentiation.
Journal ArticleDOI

Rab44, a novel large Rab GTPase, negatively regulates osteoclast differentiation by modulating intracellular calcium levels followed by NFATc1 activation.

TL;DR: Results suggest that Rab44 negatively regulates osteoclast differentiation by modulating intracellular Ca2+ levels followed by NFATc1 activation, which affects nuclear factor of activated T-cells c1 signaling in RANKL-stimulated macrophages.
Journal ArticleDOI

The Coffee Diterpene Kahweol Prevents Osteoclastogenesis via Impairment of NFATc1 Expression and Blocking of Erk Phosphorylation

TL;DR: It is shown that kahweol in coffee is a useful constituent for inhibition of OCL differentiation and up-regulated heme oxygenase-1 and inhibited high mobility group box 1 release.
Journal ArticleDOI

Deltamethrin inhibits osteoclast differentiation via regulation of heme oxygenase-1 and NFATc1.

TL;DR: It is shown that deltamethrin inhibited OCL differentiation in vitro and possibly affects bone metabolism by inhibition of nuclear factor kappa B alpha (IκBα) compared with untreated OCLs.
Journal ArticleDOI

Inhibitory effects of tert-butylhydroquinone on osteoclast differentiation via up-regulation of heme oxygenase-1 and down-regulation of HMGB1 release and NFATc1 expression.

TL;DR: This study investigated the effects of tert‐butylhydroquinone (tBHQ), a pharmacological HO‐1 inducer, on in vitro differentiation of bone marrow‐derived macrophages or murine monocytic cell line RAW‐D into OCLs and inhibited the release of high mobility group box 1 (HMGB1), a recently identified activator of OCL differentiation.